Basic Information
PARSABIV SOLUTION FOR INJECTION 10 mg/2 mL
INJECTION, SOLUTION
Regulatory Information
SIN15452P
March 14, 2018
Prescription Only
Therapeutic
INTRAVENOUS
August 10, 2023
June 4, 2025
XH05BX04
Company Information
AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD
AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD
Active Ingredients
Strength: 10 mg/2 mL
Detailed Information
Contraindications
**4.3 Contraindications** Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Parsabiv should not be initiated if corrected serum calcium is less than the lower limit of the normal range (see sections 4.2 and 4.4 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_).
Indication Information
**4.1 Therapeutic indications** Parsabiv is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.